August 5, 2014 / 8:56 PM / 4 years ago

Cytori suspends enrollment in cell therapy trials

Aug 5 (Reuters) - Cytori Therapeutics Inc said it has suspended enrollments in two trials of its experimental cell therapy for heart failure patients after a safety review.

The company’s shares fell 13 percent in extended trade.

Cerebrovascular events - those related to blood vessels in the brain - were reported in studies to evaluate safety and feasibility of adipose-derived regenerative cells in patients with ischemic heart disease, the company said.

Symptoms occurred in three patients, the company said. Two patients’ symptoms fully resolved within a short period, it said, while the third has experienced a substantial resolution.

Cytori’s shares closed at $2.10 on the Nasdaq on Tuesday. (Reporting by Shailesh Kuber; Editing by Ted Kerr)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below